SESSION TITLE: Medical Student/Resident Occupational and Environmental Lung Disease SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: October 18-21, 2020 INTRODUCTION: Vaping or e-cigarettes use has been previously marketed as a safe alternative to smoking. However, the outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) has become a public health disaster leading to the hospitalization of thousands of young, healthy individuals. Currently there is limited data available on the residual lung disease that develops after EVALI. CASE PRESENTATION: The case series included 8 patients, ages 21-46, hospitalized in the Southern California region during 2019. They presented with symptoms of unexplained dyspnea that were found to be responsive to corticosteroid treatment. All met the CDC surveillance case definition for severe pulmonary disease associated with e-cigarette use (1). DISCUSSION: The case series demonstrated heterogenous patterns of airway-centered, bronchiolocentric, interstitial pneumonia concerning for inhalation-induced lung injury. Common radiographic patterns included patchy consolidations (7/8, 87.5%), ground-glass opacification (8/8, 100%), centrilobular nodules (8/8, 100%), subpleural sparing (5/8, 62.5%), interlobular septal thickening (8/8, 100%), bronchial wall thickening (8/8, 100%), and pleural effusions (4/8, 50%). These findings of acute lung injury, including diffuse alveolar damage, organizing pneumonia and bronchiolitis were consistent with the histopathological findings recently reported by Mukhopadhyay and Butt (2,3). Radiographic findings demonstrated the presence of patchy consolidations and ground-glass opacifications in the earlier phase of disease, and the persistence of ill-defined centrilobular nodular opacifications, and the development of reticulations with traction bronchiectasis in the later phase. These radiographic patterns should be utilized in the setting of unexplained dyspnea and respiratory failure for early diagnosis and treatment of EVALI. A consistent pathologic finding was the presence of small, fine intracytoplasmic vacuoles within the foamy macrophages consistent with an endogenous source of lipids. These foamy macrophages are commonly associated with an obstructive pathology, such as small airway diseases or bronchiolitis that may present with a diffuse infiltrative pneumonia. The presence of lipid-laden macrophages should be seen as a pathological entity, and in the appropriate clinical scenario may be utilized as a sign of exposure in EVALI. CONCLUSIONS: This case series presented novel patterns of EVALI that were concerning for both alveolar damage and bronchiolar destruction. These patterns, included diffuse alveolar damage, organizing pneumonia and bronchiolitis. It also raised concerns for potential complications of EVALI, such as the development of bronchiectasis and obstructive lung diseases. We encourage physicians to discourage the use of e-cigarette products in these patients, and to maintain close follow-up for monitoring of long term sequelae of disease. Reference #1: CDC. (2020). Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html Reference #2: Mukhopadhyay, S., Mehrad, M., Dammert, P., Arrossi, A. V., Sarda, R., Brenner, D. S., ... & Ghobrial, M. (2019). Lung Biopsy Findings in Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping). American journal of clinical pathology. Reference #3: Butt, Y. M., Smith, M. L., Tazelaar, H. D., Vaszar, L. T., Swanson, K. L., Cecchini, M. J., ... & Khoor, A. (2019). Pathology of vaping-associated lung injury. New England journal of medicine, 381(18), 1780-1781. DISCLOSURES: No relevant relationships by Patrick Baghdasaryan, source=Web Response No relevant relationships by Twinkle Chandak, source=Web Response No relevant relationships by Tim Cheng, source=Web Response No relevant relationships by Matthew Crabtree, source=Web Response Industry Sponsored Research Trial relationship with PulmonX Please note: $5001 - $20000 Added 04/13/2020 by David Hsia, source=Web Response, value=Grant/Research Support Removed 04/13/2020 by David Hsia, source=Web Response Industry Sponsored Research Trial relationship with PulmonX Please note: $1001 - $5000 Added 04/13/2020 by David Hsia, source=Web Response, value=Grant/Research Support No relevant relationships by Thomas Jiang, source=Web Response No relevant relationships by Madlena Nalbandian, source=Web Response No relevant relationships by Janine Vintch, source=Web Response No relevant relationships by Fady Youssef, source=Web Response
Read full abstract